Clinical trial
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
NCT00446082 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- June 30, 2006
- Completion date
- November 30, 2013
- Enrollment
- 85 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.